盐酸替罗非班对急性冠状动脉综合征患者早期应用的疗效研究

Study on Therapeutic Effect of Tirofiban Hydrochlorid in Early-period Acute Coronary Syndrome

目的探讨盐酸替罗非班对急性冠状动脉综合征(ACS)发生早期(24～72h)的治疗效果及安全性。方法将100例被确诊为ACS的患者随机分为常规治疗组50例和盐酸替罗非班治疗组50例,前者只给常规治疗,后者给予常规治疗加盐酸替罗非班持续泵入72h。用ELISA法测定100例ACS患者治疗前后血清sCD40L水平并观察两组患者1个月内心脏复合终点事件的发生率及出血的比例。结果盐酸替罗非班治疗组50例ACS患者经治疗后血清sCD40L水平明显下降,与常规治疗组比较有显著统计学差异(P<0.01),其心脏复合终点事件发生率亦明显低于常规治疗组(P<0.05)。两组出血的比例无显著差异。结论盐酸替罗非班用于ACS患者的早期治疗,可明显降低患者的血清炎症因子水平,不良反应少,值得临床推广。

Objective To study the effect and safety of tirofiban hydrochlorid in patients with acute coronary syndromes （ACS） during their early- period （24--72 h）. Methods A total of 100 patients with initially diagnosed ACS were divided into two groups. Fifty cases were treated with routine approaches and 50 cases were treated with additional tirofiban hydrochloride. Serum CD40L levels were monitored with ELISA. The incidence of primary composite end point and the bleeding incidence were analyzed and compared between the two groups, Results Serum CD40L level was decreased significantly in patients treated with tirofiban hydrochloride compared with that of the patients treated with routine approach （P 〈 0 . 01 ）. The incidence of the primary composite end point in tirofiban group was significantly lower than that in the control group （ P 〈 0.05）, but no significant difference in the bleeding incidence was found between them. Conclusion Early treatment of ACS with tirofiban hydrochloride can significantly decrease the serum inflammatory cytokines and reduce the incidence of ischemic/thrombotic complications.